Corbus Pharmaceuticals Holdings Inc (CRBP)
39.10
+2.62
(+7.18%)
USD |
NASDAQ |
Apr 19, 16:00
38.46
-0.64
(-1.64%)
After-Hours: 16:40
Corbus Pharmaceuticals Holdings Enterprise Value: 378.61M for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 378.61M |
| April 17, 2024 | 385.75M |
| April 16, 2024 | 427.36M |
| April 15, 2024 | 444.17M |
| April 12, 2024 | 424.52M |
| April 11, 2024 | 415.59M |
| April 10, 2024 | 396.15M |
| April 09, 2024 | 389.01M |
| April 08, 2024 | 417.27M |
| April 05, 2024 | 415.28M |
| April 04, 2024 | 404.77M |
| April 03, 2024 | 399.83M |
| April 02, 2024 | 388.90M |
| April 01, 2024 | 394.47M |
| March 28, 2024 | 407.61M |
| March 27, 2024 | 369.04M |
| March 26, 2024 | 375.14M |
| March 25, 2024 | 369.67M |
| March 22, 2024 | 362.42M |
| March 21, 2024 | 395.61M |
| March 20, 2024 | 406.32M |
| March 19, 2024 | 443.99M |
| March 18, 2024 | 432.03M |
| March 15, 2024 | 453.64M |
| March 14, 2024 | 468.86M |
| Date | Value |
|---|---|
| March 13, 2024 | 489.32M |
| March 12, 2024 | 463.09M |
| March 11, 2024 | 396.98M |
| March 08, 2024 | 466.76M |
| March 07, 2024 | 412.08M |
| March 06, 2024 | 342.41M |
| March 05, 2024 | 352.96M |
| March 04, 2024 | 370.74M |
| March 01, 2024 | 357.09M |
| February 29, 2024 | 314.71M |
| February 28, 2024 | 284.73M |
| February 27, 2024 | 264.78M |
| February 26, 2024 | 290.11M |
| February 23, 2024 | 261.48M |
| February 22, 2024 | 258.37M |
| February 21, 2024 | 275.95M |
| February 20, 2024 | 236.15M |
| February 16, 2024 | 234.08M |
| February 15, 2024 | 227.67M |
| February 14, 2024 | 227.88M |
| February 13, 2024 | 222.71M |
| February 12, 2024 | 233.05M |
| February 09, 2024 | 224.26M |
| February 08, 2024 | 218.89M |
| February 07, 2024 | 243.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-40.47M
Minimum
May 12 2022
703.09M
Maximum
Sep 02 2020
137.63M
Average
46.94M
Median
Oct 04 2021
Enterprise Value Benchmarks
| Panbela Therapeutics Inc | 4.992M |
| Processa Pharmaceuticals Inc | -0.2508M |
| Protalix BioTherapeutics Inc | 58.24M |
| Spectral AI Inc | 24.01M |
| Vera Therapeutics Inc | 2.039B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.021M |
| Total Expenses (Quarterly) | 10.10M |
| EPS Diluted (Quarterly) | -1.79 |
| Earnings Yield | -26.47% |
| Normalized Earnings Yield | -31.29 |